Sunil Suhas Solomon1, Thomas C Quinn2, Suniti Solomon3, Allison M McFall4, Aylur K Srikrishnan3, Vinita Verma5, Muniratnam S Kumar3, Oliver Laeyendecker6, David D Celentano7, Syed H Iqbal3, Santhanam Anand3, Canjeevaram K Vasudevan3, Shanmugam Saravanan3, David L Thomas4, Kuldeep Singh Sachdeva5, Gregory M Lucas4, Shruti H Mehta7. 1. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: sss@jhmi.edu. 2. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 3. YR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India. 4. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. National AIDS Control Organisation, Ministry of Health and Family Welfare, New Delhi, India. 6. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. 7. Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Abstract
BACKGROUND & AIMS: There have been calls to integrate HCV testing into existing services, including harm reduction and HIV prevention and treatment, but there are few empirical trials to date. We evaluated the impact of integrating HCV testing/education into integrated care centers (ICCs) delivering HIV services to people who inject drugs (PWID) across India, using a cluster-randomized trial. METHODS: We compared ICCs with usual care in the PWID stratum (12 sites) of a 22-site cluster-randomized trial. In 6 sites, ICCs delivering HIV testing, harm reduction, other preventive services and linkage to HIV treatment were scaled from opioid agonist therapy centers and operated for 2 years. On-site rapid HCV antibody testing was integrated after 1 year. To assess impact, we conducted baseline and evaluation surveys using respondent-driven sampling (RDS) across the 12 sites (n = 11,993 recruited at baseline; n = 11,721 recruited at evaluation). The primary outcome was population-level self-reported HCV testing history. RESULTS: At evaluation, HCV antibody prevalence ranged from 7.2-76.6%. Across 6 ICCs, 5,263 ICC clients underwent HCV testing, of whom 2,278 were newly diagnosed. At evaluation, PWID in ICC clusters were 4-fold more likely to report being tested for HCV than in usual care clusters, adjusting for baseline testing (adjusted prevalence ratio [aPR] 3.69; 95% CI 1.34-10.2). PWID in ICC clusters were also 7-fold more likely to be aware of their HCV status (aPR 7.11; 95% CI 1.14-44.3) and significantly more likely to initiate treatment (aPR 9.86; 95% CI 1.52-63.8). CONCLUSIONS: We provide among the first empirical data supporting the integration of HCV testing into HIV/harm reduction services. To achieve elimination targets, programs will need to scale-up such venues to deliver comprehensive HCV services. CLINICALTRIALS. GOV IDENTIFIER: NCT01686750. LAY SUMMARY:Delivering hepatitis C virus (HCV) testing to people who inject drugs (PWID) in places where they also have access to HIV prevention and treatment services is an effective way to improve uptake of HCV testing among communities of PWID. To achieve the World Health Organization's ambitious elimination targets, integrated programs will need to be scaled up to deliver comprehensive HCV services.
RCT Entities:
BACKGROUND & AIMS: There have been calls to integrate HCV testing into existing services, including harm reduction and HIV prevention and treatment, but there are few empirical trials to date. We evaluated the impact of integrating HCV testing/education into integrated care centers (ICCs) delivering HIV services to people who inject drugs (PWID) across India, using a cluster-randomized trial. METHODS: We compared ICCs with usual care in the PWID stratum (12 sites) of a 22-site cluster-randomized trial. In 6 sites, ICCs delivering HIV testing, harm reduction, other preventive services and linkage to HIV treatment were scaled from opioid agonist therapy centers and operated for 2 years. On-site rapid HCV antibody testing was integrated after 1 year. To assess impact, we conducted baseline and evaluation surveys using respondent-driven sampling (RDS) across the 12 sites (n = 11,993 recruited at baseline; n = 11,721 recruited at evaluation). The primary outcome was population-level self-reported HCV testing history. RESULTS: At evaluation, HCV antibody prevalence ranged from 7.2-76.6%. Across 6 ICCs, 5,263 ICC clients underwent HCV testing, of whom 2,278 were newly diagnosed. At evaluation, PWID in ICC clusters were 4-fold more likely to report being tested for HCV than in usual care clusters, adjusting for baseline testing (adjusted prevalence ratio [aPR] 3.69; 95% CI 1.34-10.2). PWID in ICC clusters were also 7-fold more likely to be aware of their HCV status (aPR 7.11; 95% CI 1.14-44.3) and significantly more likely to initiate treatment (aPR 9.86; 95% CI 1.52-63.8). CONCLUSIONS: We provide among the first empirical data supporting the integration of HCV testing into HIV/harm reduction services. To achieve elimination targets, programs will need to scale-up such venues to deliver comprehensive HCV services. CLINICALTRIALS. GOV IDENTIFIER: NCT01686750. LAY SUMMARY: Delivering hepatitis C virus (HCV) testing to people who inject drugs (PWID) in places where they also have access to HIV prevention and treatment services is an effective way to improve uptake of HCV testing among communities of PWID. To achieve the World Health Organization's ambitious elimination targets, integrated programs will need to be scaled up to deliver comprehensive HCV services.
Authors: Sunil S Solomon; Suniti Solomon; Allison M McFall; Aylur K Srikrishnan; Santhanam Anand; Vinita Verma; Canjeevaram K Vasudevan; Pachamuthu Balakrishnan; Elizabeth L Ogburn; Lawrence H Moulton; Muniratnam S Kumar; Kuldeep Singh Sachdeva; Oliver Laeyendecker; David D Celentano; Gregory M Lucas; Shruti H Mehta Journal: Lancet HIV Date: 2019-04-02 Impact factor: 12.767
Authors: Paul Y Kwo; Fred Poordad; Armen Asatryan; Stanley Wang; David L Wyles; Tarek Hassanein; Franco Felizarta; Mark S Sulkowski; Edward Gane; Benedict Maliakkal; J Scott Overcash; Stuart C Gordon; Andrew J Muir; Humberto Aguilar; Kosh Agarwal; Gregory J Dore; Chih-Wei Lin; Ran Liu; Sandra S Lovell; Teresa I Ng; Jens Kort; Federico J Mensa Journal: J Hepatol Date: 2017-04-13 Impact factor: 25.083
Authors: Guthrie S Birkhead; Susan J Klein; Alma R Candelas; Daniel A O'Connell; Jeffrey R Rothman; Ira S Feldman; Dennis S Tsui; Richard A Cotroneo; Colleen A Flanigan Journal: Int J Drug Policy Date: 2007-02-20
Authors: Zameer Mohamed; John Rwegasha; Jin U Kim; Yusuke Shimakawa; Lila Poiteau; Stéphane Chevaliez; Sanjay Bhagani; Simon D Taylor-Robinson; Mark R Thursz; Jessie Mbwambo; Maud Lemoine Journal: J Viral Hepat Date: 2018-07-30 Impact factor: 3.728
Authors: Graham R Foster; Nezam Afdhal; Stuart K Roberts; Norbert Bräu; Edward J Gane; Stephen Pianko; Eric Lawitz; Alex Thompson; Mitchell L Shiffman; Curtis Cooper; William J Towner; Brian Conway; Peter Ruane; Marc Bourlière; Tarik Asselah; Thomas Berg; Stefan Zeuzem; William Rosenberg; Kosh Agarwal; Catherine A M Stedman; Hongmei Mo; Hadas Dvory-Sobol; Lingling Han; Jing Wang; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Francesco Mazzotta; Tram T Tran; Stuart C Gordon; Keyur Patel; Nancy Reau; Alessandra Mangia; Mark Sulkowski Journal: N Engl J Med Date: 2015-11-17 Impact factor: 91.245
Authors: Sally Hopewell; Mike Clarke; David Moher; Elizabeth Wager; Philippa Middleton; Douglas G Altman; Kenneth F Schulz Journal: PLoS Med Date: 2008-01-22 Impact factor: 11.069
Authors: Louisa Degenhardt; Amy Peacock; Samantha Colledge; Janni Leung; Jason Grebely; Peter Vickerman; Jack Stone; Evan B Cunningham; Adam Trickey; Kostyantyn Dumchev; Michael Lynskey; Paul Griffiths; Richard P Mattick; Matthew Hickman; Sarah Larney Journal: Lancet Glob Health Date: 2017-10-23 Impact factor: 26.763
Authors: Bao Ngoc Vu; Kim Do Tuan; An Khanh Tran; Long Khanh Tran; Kimberly Green; Khoa Trong Nguyen; Phuong Duc Cao Journal: Clin Liver Dis (Hoboken) Date: 2022-04-29
Authors: Lisa R Metsch; Daniel J Feaster; Lauren K Gooden; Carmen Masson; David C Perlman; Mamta K Jain; Tim Matheson; C Mindy Nelson; Petra Jacobs; Susan Tross; Louise Haynes; Gregory M Lucas; Jonathan A Colasanti; Allan Rodriguez; Mari-Lynn Drainoni; Georgina Osorio; Ank E Nijhawan; Jeffrey M Jacobson; Meg Sullivan; David Metzger; Pamela Vergara-Rodriguez; Ronald Lubelchek; Rui Duan; Jacob N Batycki; Abigail G Matthews; Felipe Munoz; Eve Jelstrom; Raul Mandler; Carlos Del Rio Journal: Open Forum Infect Dis Date: 2021-06-27 Impact factor: 4.423
Authors: Caroline A Bulstra; Jan A C Hontelez; Moritz Otto; Anna Stepanova; Erik Lamontagne; Anna Yakusik; Wafaa M El-Sadr; Tsitsi Apollo; Miriam Rabkin; Rifat Atun; Till Bärnighausen Journal: PLoS Med Date: 2021-11-09 Impact factor: 11.069
Authors: Eshan U Patel; Sunil S Solomon; Gregory M Lucas; Allison M McFall; Cecília Tomori; Aylur K Srikrishnan; Muniratnam S Kumar; Oliver Laeyendecker; David D Celentano; David L Thomas; Thomas C Quinn; Shruti H Mehta Journal: Int J Drug Policy Date: 2021-07-08